Dec 26, 2021

Digital Healthcare award for CENTOGENE

healthcare
digitalhealthcare
healthi
Biomarker
Helen Adams
2 min
Digital healthcare
Biotechnology company CENTOGENE has won the Health-i award in digital healthcare innovation for its artificial intelligence platform

Centogene a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it has been awarded the Health-i Award, which recognizes companies that are transforming healthcare in Germany and beyond.

Founded in 2006 and headquartered in Rostock, Germany, Centogene diagnoses rare diseases, using its knowledge and expanding collection of data.

 

AI-powered biomarker platform

The Health-i Award winners are chosen by industry and research experts, across groups which are advancing healthcare innovation. 

Centogene won for its AI-powered biomarker platform, CentoMetabolome. 

Biomarkers enable healthcare professionals to identify the details of a disease.

The CentoMetabolome platform can transform the way biomarkers are detected - meaning research, diagnosis and treatment can be conducted much faster, leading to recovery.

Germany’s Health-i Awards are sponsored by:

  • Germany’s biggest public health insurance provider Techniker Krankenkasse
  • German newspaper Handelsblatt

 

Artificial intelligence supports digital health innovations

This AI development is another proud step forward for CENTOGENE’s mission to cure more diseases.

“We are proud to be recognised for our impact in the healthcare industry and the innovation we are bringing with our unique leading metabolomics platform”, said Carsten Ullrich, Senior Director of Artificial Intelligence. “Working together across several departments, we have been able to fully leverage CENTOGENE’s expertise in omics, extensive global insights from our rare disease-centric Bio/Databank, and advanced AI tools. 

“As a result, we can now analyse the dynamics of diseases to drive biomarker discovery and test drug candidates as we continue our mission to enable the cure of 100 rare diseases in 10 years.” 

 

Share article